Fresh Tracks Therapeutics, Inc. (FRTX) Stock

About Fresh Tracks Therapeutics, Inc.

Fresh Tracks Therapeutics, Inc. is a clinical-stage pharmaceutical firm focused on creating diverse prescription therapies to address a range of severe autoimmune, inflammatory, and other chronic debilitating conditions, primarily within the U.S. market. A key compound in its development pipeline is sofpironium bromide, which has successfully completed Phase III clinical trials for the management of primary axillary hyperhidrosis. The company is also advancing BBI-02, an oral DYRK1A inhibitor targeting autoimmune and inflammatory diseases, and BBI-10, a covalent STING pathway inhibitor with potential for treating autoinflammatory and rare genetic disorders. Furthermore, Fresh Tracks is engaged in developing next-generation kinase inhibitors. The company maintains crucial licensing and collaborative partnerships, including agreements with Carna Biosciences, Inc., Voronoi Inc., Bodor Laboratories, Inc. (and Dr. Nicholas S. Bodor), and AnGes, Inc. Founded in 2009 and based in Boulder, Colorado, the organization rebranded in September 2022, previously operating under the name Brickell Biotech, Inc.

Fresh Tracks Therapeutics, Inc. is headquartered in US.

Fresh Tracks Therapeutics, Inc. (FRTX) stock trades at $0.94 with a market capitalization of $5.59M. The stock is valued at a price-to-earnings (P/E) ratio of -0.97, price-to-book of 0.56, price-to-sales of 0.70. Over the past 52 weeks the stock has ranged between $0.03 and $1.03, and currently trades 8.7% below its 52-week high.

On profitability, Fresh Tracks Therapeutics, Inc. generates a return on equity (ROE) of -66.50%, return on capital employed of -64.05%, an operating margin of -79.44%, a net profit margin of -71.12%.

Official website: www.frtx.com